Scarica l'app Stockscreener
8.99
5.52%
0.47
Precedente Chiudi:
$8.52
Aprire:
$8.62
Volume 24 ore:
3.69M
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.04B
Reddito:
$52.86M
Utile/perdita netta:
$-480.19M
Rapporto P/E:
-1.9169
EPS:
-4.6899
Flusso di cassa netto:
$-421.82M
1 W Prestazione:
+9.50%
1M Prestazione:
-35.60%
6M Prestazione:
-6.94%
1 anno Prestazione:
-40.89%
Intervallo 1D:
$8.53
$9.10
Intervallo di 1 settimana:
$8.135
$9.10
Portata 52W:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.99 | 986.87M | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Pullback Watch: Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Weekly Recap & Intraday High Probability Alerts - moha.gov.vn
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? - Zacks Investment Research
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Will Intellia Therapeutics Inc. stock remain a Wall Street favorite2025 Geopolitical Influence & Accurate Intraday Trading Signals - moha.gov.vn
Operating cash flow per share of Intellia Therapeutics, Inc. – LSX:A2AG6H - TradingView
Is Intellia Therapeutics Inc 38I a good long term investmentDividend Yield Trends & These Picks Are Just One Breakout Away - earlytimes.in
5 Stocks with the Largest Fair Value Estimate Cuts After Q3 Earnings - Morningstar
Intellia Therapeutics Shares: A Crisis Crossroads - Ad-hoc-news.de
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress - Insider Monkey
9 Oversold Biotech Stocks to Invest In - Insider Monkey
NTLA Stockholders Have Opportunity to Lead Intellia Therapeutics - The National Law Review
Intellia Therapeutics, Inc. Sued for Securities Law Violations – - The National Law Review
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Finviz
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Remind - The National Law Review
Is Intellia Therapeutics Attractive After a 70.6% Drop and Latest Clinical Trial Update? - Yahoo Finance
Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Will Intellia Therapeutics Inc. (38I) stock outperform value peersEntry Point & AI Forecasted Entry/Exit Points - newser.com
What technical models suggest about Intellia Therapeutics Inc.’s comebackWeekly Trend Summary & AI Powered Market Trend Analysis - newser.com
How Intellia Therapeutics Inc. stock reacts to oil pricesJuly 2025 Earnings & Trade Opportunity Analysis Reports - newser.com
Can Intellia Therapeutics Inc. stock deliver surprise earnings beatMarket Movers & Free Real-Time Volume Trigger Notifications - newser.com
Can volume confirm reversal in Intellia Therapeutics Inc.2025 Price Targets & Long Hold Capital Preservation Tips - newser.com
Will Intellia Therapeutics Inc. (38I) stock recover faster than industryJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Intellia Therapeutics: A Worst-Case Risk Becomes A Tragic Reality (Downgrade) - Seeking Alpha
Why Intellia Therapeutics Inc. (38I) stock remains top ratedJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Intellia Therapeutics (NTLA): Exploring Valuation as Investors Digest Latest Quarterly Update - Sahm
Is Intellia Therapeutics Inc. still worth holding after the dipJuly 2025 Update & Community Supported Trade Ideas - newser.com
Can Intellia Therapeutics Inc. stock deliver strong Q4 earnings2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Intellia Therapeutics Faces Weak Start with 10.21% Gap Down Amid Market Concerns - Markets Mojo
What data driven models say about Intellia Therapeutics Inc.’s futureFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data - Insider Monkey
9 Best Gene-Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Intellia Therapeutics Shares Plunge on Clinical Trial Safety Concerns - AD HOC NEWS
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intellia Therapeutics Inc Azioni (NTLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer |
Oct 01 '25 |
Sale |
17.38 |
1,871 |
32,518 |
55,266 |
| CHASE WILLIAM J | Director |
Aug 20 '25 |
Buy |
10.03 |
100,000 |
1,003,000 |
134,693 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
0.45%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):